A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

Launched by BRISTOL-MYERS SQUIBB · Jul 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called deucravacitinib to see how well it works for adults with moderate plaque psoriasis in China. Plaque psoriasis is a skin condition that causes red, flaky patches to appear on the skin, and this study aims to gather real-world information about how effective the treatment is for patients who are just starting to use it.

To be eligible for the trial, participants need to be at least 18 years old and have been diagnosed with moderate plaque psoriasis by a dermatologist. This means their skin condition affects between 3% and 10% of their body surface area. They should not be taking other psoriasis treatments or have used deucravacitinib before. Those who join the study will provide their consent to participate and will be monitored to gather information about their treatment experience. This trial is currently recruiting participants, and it’s an important opportunity to help understand how this new treatment works in everyday settings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant aged 18 years or older
• • Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and \< 10%
• • Participant newly initiated deucravacitinib according to the label
• • Provided written informed consent to participate in the study
• Exclusion Criteria:
• • Participating in or planning to participate in an interventional clinical trial
• • Concomitant use of other systemic treatments for psoriasis at baseline
• • Prior treatment of deucravacitinib